Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | STK4 | Q13043 | 1/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112508 | 0.85 | LRRK2 (0.54) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2600622 | 0.85 | LRRK2 (0.57) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2113093 | 0.85 | LRRK2 (0.54) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2600618 | 0.84 | LRRK2 (0.53) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2112310 | 0.82 | LRRK2 (0.52) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2112456 | 0.81 | LRRK2 (0.51) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2600617 | 0.78 | LRRK2 (0.47) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL2112309 | 0.76 | LRRK2 (0.51) | LRRK2JAK3JAK2STK4STK3 | |
| SCHEMBL1516570 | 0.74 | DYRK1A (0.62) | LRRK2JAK3JAK2STK3ABL1 | |
| SCHEMBL28057749 | 0.73 | LRRK2 (0.70) | LRRK2JAK3JAK2STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | LRRK2 1040/4885JAK3 90/4885JAK2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.